Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Falling Comet
1954.0000 -7.10 (-0.36%)
NSE Jun 03, 2025 15:31 PM
Volume: 681.1K
 

logo
Lupin Ltd.
16 May 2025
1954.00
-0.36%
Prabhudas Lilladhar
Lupin's (LPC) Q4FY25 EBITDA was at Rs13bn (up 30% YoY) ~10% beat to our estimates on the back of higher US sales supported by niche launches. GMs improved YoY. LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23-24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY26E stands increase by 5% as we factor...
Lupin Ltd. is trading below all available SMAs
More from Lupin Ltd.
Recommended